Study of Cabergoline in Treatment of Corticotroph Pituitary Tumor

Seth Gordhandas Sunderdas Medical College

Overview

This study was designed to check the efficacy of a new oral medical drug treatment, namely Cabergoline, for the treatment of Cushing Disease due to pituitary adenoma. Background: Cabergoline is a Dopamine 2 receptor agonist. Corticotroph adenoma has shown to have the D2 receptor in in vitro studies.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Conditions

Cushing's Disease Corticotroph Adenoma

Interventions

CabergolineDRUG

Dose 1 mg/week in divided doses, increased by 1 mg/week every month, to the maximum of 5 mg/week. If response is seen than the dose at which response is seen is continued until the end of the study.

Eligibility

Sex: ALLMin age: 12 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patient with Cushing's disease uncured biochemically after pituitary surgery with adenoma on histopathology Exclusion Criteria: * Patient's intolerance to drug or known sensitivity to ergot derivatives * Pregnancy, lactation or female wishing to be pregnant * Any serious medical illness * Patient on any drugs known to have an interaction with cabergoline including antihypertensives like reserpine and methyl dopa, neuroleptics, metoclopramide, etc

Locations (1)

Seth GSMC & KEM hospital

Mumbai, Maharashtra, India

Outcomes

Primary Outcomes

Response in term of mid night cortisol < 5.0 mcg/dl and/or Standard two day dexamethasone suppression test < 1.8 mcg/dl

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.